E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Predictors of adverse psychological experiences surrounding genome-wide profiling for disease risk
K. M. Broady,Kelly E. Ormond,Eric J. Topol,Nicholas J. Schork,Cinnamon S. Bloss,Cinnamon S. Bloss +5 more
TL;DR: A secondary analysis on data from the Scripps Genomic Health Initiative (SGHI), which studied 2037 individuals tested with commercially available tests yielding personalized risk estimates for 23 common, genetically complex diseases, identified predictors of adverse psychological experiences among direct-to-consumer genomic test consumers.
Journal ArticleDOI
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model
Michael Gottsauner-Wolf,Yangsoo Jang,A.M. Lincoff,J. L. Cohen,Vinod Labhasetwar,Earl Poptic,Farhard Forudi,Luis A. Guzman,Paul E. DiCorleto,Robert J. Levy,Eric J. Topol,Stephen G. Ellis +11 more
TL;DR: Despite inhibition of smooth-muscle cell proliferation by tyrphostin-47 in vitro, sustained local delivery of this tyrosine kinase inhibitor does not result in a reduction of neointimal proliferation in the rat carotid injury model.
Journal ArticleDOI
The Restenosis “Antitheory”
TL;DR: A major finding in this model is that the platelet-fibrin thrombus seems to function as a "bioabsorbable matrix" or colony for the migration and proliferation of cells in this large-animal model.
Journal ArticleDOI
Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue.
TL;DR: The relevant issues behind the incorporation of optimal tissue sampling techniques into routine pathologic practice are discussed and recommendations for the cancer genomic medicine of the future are made.